US drug pricing reform happens at last
As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
It’s official: Roche is a Car-T player
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
Corporate venture investors stay strong
The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.
No place for Wee1 in Astra’s synthetic lethality work
Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.
